Vigabatrin
Orphan DrugFDA Approved, EMA Approved
Description
Antiepileptic medication that inhibits GABA transaminase, increasing GABA levels in the brain. It is used for refractory complex partial seizures and infantile spasms, particularly in patients with developmental brain abnormalities.
Indications & Therapeutic Use
Infantile spasms, refractory complex partial seizures, epilepsy associated with corpus callosum dysgenesis
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Vigabatrin
| Generic Name | Vigabatrin |
| Brands | 1 brand available |
| Active Ingredient | Vigabatrin |
| Drug Class | Infantile spasms |
| Manufacturer | Lundbeck |
| Dosage Forms | Oral tablet 500mg; Oral powder for solution 500mg sachets |
| Medical Code | N03AG04 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00000110 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes